thyssenkrupp nucera (NCH2) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
23 Nov, 2025Executive summary
Sales and EBIT guidance for FY 2024/25 were raised following a solid nine-month performance, with key project milestones such as 80% completion of the NEOM green hydrogen plant and new contracts in Europe and India.
Achieved significant technology expansion through the acquisition of Green Hydrogen Systems technology and the launch of the SOEC pilot production plant in Germany.
Order intake dropped sharply in Q3, mainly due to a 94% fall in green hydrogen orders, while the core alkali segment order intake remained stable.
Paid engineering contracts totaling 1.5 GW in Europe are expected to convert to firm orders in 6–12 months, supporting a substantial order backlog of approximately EUR 0.7 billion.
Workforce increased by 149 employees year-over-year, reaching 1,093.
Financial highlights
Q3 sales declined 22% year-over-year to EUR 184 million, reflecting high prior-year base and project completion; nine-month sales rose 9% to EUR 663 million.
Q3 EBIT was flat at EUR 0 million; nine-month EBIT improved to EUR 4 million from EUR -13 million.
Net income for Q3 was -EUR 2 million; nine-month net income was EUR 4 million, with EPS at EUR 0.04.
Free cash flow improved to EUR 50 million for the nine-month period, up from -EUR 57 million prior year.
Gross margin in Q3 was 14%, up from 11% prior year; 9M gross margin up 26% to EUR 76 million.
Outlook and guidance
Full-year group sales expected between EUR 850–920 million; EBIT guidance raised to EUR -7 million to +7 million.
Green hydrogen segment sales expected at EUR 450–510 million, EBIT at -EUR 75 to -EUR 55 million; core alkali segment sales at EUR 380–420 million, EBIT at EUR 55–75 million.
Order intake in Q4, especially for green hydrogen, expected to remain subdued due to timing of FIDs and project delays.
Outlook based on execution of contracted projects and market conditions.
Latest events from thyssenkrupp nucera
- Order intake guidance raised to €550–850m, but sales and EBIT guidance lowered for FY 2025/26.NCH2
Status update18 Mar 2026 - Strong financials, strategic innovation, and all agenda items approved amid market challenges.NCH2
AGM 202625 Feb 2026 - Record chlor-alkali sales and improved margins offset green hydrogen softness; outlook cautious.NCH2
Q4 202513 Feb 2026 - Sales and EBIT declined sharply, but full-year guidance and order momentum remain strong.NCH2
Q1 202611 Feb 2026 - Record sales and robust backlog, but AWE outlook clouded by regulatory and market delays.NCH2
Q3 20241 Feb 2026 - Record sales and resilient AWE and CA growth drive strong performance amid market challenges.NCH2
Q4 202411 Jan 2026 - Record Q1 sales and EBIT growth, with strong outlook and robust order backlog.NCH2
Q1 202523 Dec 2025 - Sales and EBIT rose 31% YoY, with strong project execution and guidance confirmed.NCH2
Q2 202519 Nov 2025 - Record sales and expanding project pipeline highlight strong growth and market leadership.NCH2
Investor Presentation17 Jun 2025